Foghorn Therapeutics (FHTX) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$0.25.
- Foghorn Therapeutics' EPS (Weighted Average and Diluted) rose 19.35% to -$0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.13, marking a year-over-year increase of 41.15%. This contributed to the annual value of -$1.58 for FY2024, which is 32.48% up from last year.
- Latest data reveals that Foghorn Therapeutics reported EPS (Weighted Average and Diluted) of -$0.25 as of Q3 2025, which was up 10.71% from -$0.28 recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) registered a high of -$0.25 during Q3 2025, and its lowest value of -$0.77 during Q4 2021.
- In the last 3 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.34 in 2023 and averaged -$0.44.
- The largest annual percentage gain for Foghorn Therapeutics' EPS (Weighted Average and Diluted) in the last 5 years was 77.24% (2021), contrasted with its biggest fall of 130.43% (2021).
- Over the past 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.77 in 2021, then climbed by 10.39% to -$0.69 in 2022, then increased by 17.39% to -$0.57 in 2023, then spiked by 47.37% to -$0.30 in 2024, then increased by 19.35% to -$0.25 in 2025.
- Its last three reported values are -$0.25 in Q3 2025, -$0.28 for Q2 2025, and -$0.30 during Q1 2025.